

Urinary biomarkers in childhood Lupus Nephritis

Eve MD Smith¹, Michael W Beresford^{1,2}

¹Department of Women's & Children's Health, Institute of Translational Medicine, University of Liverpool, Institute in the Park, Alder Hey Children's NHS Foundation Trust Hospital, East Prescott Road, Liverpool, L14 5AB, UK. esmith8@liverpool.ac.uk

²Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust in the Park, East Prescott Road, Liverpool, L14 5AB, Liverpool, UK.
m.w.beresford@liverpool.ac.uk

Corresponding author: Dr Eve Smith

Abstract

Juvenile-onset systemic lupus erythematosus (JSLE) is a rare, severe multisystem autoimmune disease affecting the kidney (Lupus Nephritis, LN) in up to 80% of children. LN is more severe in children than adults, with potential for irreversible kidney damage requiring dialysis or transplant. Renal biopsy is currently the gold standard for diagnosing and monitoring LN, however, it is invasive and associated with complications. Urine biomarkers have been shown to be better than serum biomarkers in differentiating renal disease from other organ manifestations. Over the past decade, there have been an increasing number of studies investigating specific candidate biomarkers implicated in the pathogenesis of LN or screening for urinary biomarkers using hypothesis free methods. In this review, developments in urine biomarkers for LN will be reviewed, highlighting those that are of relevance to children and have gone through validation in independent international patient cohorts, bringing them close to clinical translation.

Keywords

Urine, biomarkers, Lupus Nephritis, Childhood Lupus, JSLE

Abbreviations

AGP = α -1 acid glycoprotein,
ANA = anti-nuclear antigen
AUC = area under the curve
 β 2MG = Beta-2-microglobulin
BILAG = British Isles Lupus Assessment Group score
C3 = complement factor 3
C4 = complement factor 4
CKD = chronic kidney disease patients
CrCl = creatinine clearance
CXCL16 = Chemokine (C-X-C motif) ligand 16
CXCR3 = Chemokine receptor 3

Fn14 = fibroblast growth factor-inducible 14
 FLCs = free light chains
 FSGS = focal segmental glomerulosclerosis
 GFR = glomerular filtration rate
 HC's = healthy controls
 IFN- γ = interferon gamma
 IL = interleukin
 IP-10 = Interferon- γ -inducible protein 10
 ISN/RPS = International Society of Nephrology / Renal Pathology Society
 JIA = juvenile idiopathic arthritis
 JSLE = Juvenile-onset systemic lupus erythematosus
 K-FLC = κ free light chain
 KIM-1 = kidney injury molecule 1
 L-FLC = lamda free light chains
 LC-MS = Liquid chromatography coupled to mass spectrometry
 LC/MS/MS = liquid chromatography-nanospray tandem mass spectrometry
 LN = lupus nephritis
 MALDI-TOF MS = Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
 MCP-1 = Monocyte chemoattractant protein-1
 NIH = National Institute for Health
 NGAL = Neutrophil gelatinase associated lipoclain
 PGDS = Prostaglandin-H2-D isomerase, alternative name LPGDS
 RA = rheumatoid arthritis
 RANTES = regulated on activation, normal T cell expressed and secreted
 RBP-4 = retinol binding protein 4
 ROC = receiver operating curve
 SELDI-TOF = Surface-enhanced laser desorption/ionization time of flight technology
 SLE = systemic lupus erythematosus
 SLEDAI = SLE disease activity index
 SLICC = Systemic Lupus Collaborating Clinics
 TF = transferrin
 TWEAK = Tumor necrosis factor (TNF)-like weak inducer of apoptosis
 VCAM-1 = Vascular cell adhesion molecule-1
 WHO = world health organization
 ZA2G = Zn-alpha2-glycoprotein

1 Introduction

Juvenile-onset systemic lupus erythematosus (JSLE), also known as childhood-onset SLE, is a rare, severe multisystem autoimmune disease. Twenty percent of cases of SLE are diagnosed during childhood, with up to 80% of JSLE patients developing lupus nephritis (LN) [1], compared with 40-50% in adults [2,3]. LN may be part of the patients' initial presentation or occur later in the disease. Renal biopsy is currently the gold standard for diagnosing LN, characterizing disease activity and providing insight into the degree of scarring and irreversible damage to the kidney [4,5]. However, the invasive nature of the procedure, risk of complications such as bleeding or infection, and need for anaesthetic in children, lead to a tendency for the procedure to be avoided until deemed absolutely necessary. Clinicians therefore rely heavily upon less invasive markers including proteinuria, serum creatinine, glomerular filtration rate (GFR), urine microscopy, immunological, hematological and

inflammatory biomarkers when monitoring patients and making a decision whether to undertake a renal biopsy. At present, there is no consensus as to the optimal timing of an initial renal biopsy for diagnosing LN in children, with clinical concern that irreversible renal damage may occur prior to the onset of clinically overt disease [6].

Following a histological diagnosis of LN, on-going monitoring tends to again rely on the above blood and urine tests, however, these investigations have many limitations which require recognition. Following a LN flare, proteinuria can take a significant period of time to normalize, making it difficult to differentiate proteinuria due to irreversible damage of the glomerular capillaries or on-going LN activity [7]. Changes in serum creatinine tend to lag behind changes in glomerular filtration rate and are also influenced by the child's age, gender and height [8]. Of concern, there have been reports of 'clinically silent LN' in patients with biopsy defined LN but no proteinuria, normal urinalysis and normal renal function [9]. Repeat biopsy of patients who have shown a complete clinical renal response has found approximately one third to have on-going evidence of LN activity, and approximately 60% to display chronicity index features [10]. Normal complement and anti-dsDNA antibodies may provide reassurance that active LN is improbable, however, studies looking at the accuracy of these tests for differentiating between patients with active and in-active LN have shown conflicting results [11-13].

2 Pursuit of novel biomarkers for LN

Clearly, the performance of conventional blood and urine tests for LN diagnosis and monitoring is inadequate. LN therapy could be more effective, treatment toxicity limited, and renal outcomes improved if LN onset, severity, and treatment responsiveness could be predicted. Early treatment and rapid induction of LN remission has been shown to improve renal survival, highlighting the need for improved LN detection and monitoring [14,15]. To this end, novel, non-invasive biomarkers of disease activity and prognosis are increasingly being investigated. To translate an experimental biomarker into clinical practice, Mischak et al [16] describe a six step process which we should be mindful of when evaluating novel biomarkers studies. This process includes: (1) initial biomarker identification / verification, (2) evaluation of the results by independent experts, (3) evaluation in a suitable bio bank of existing samples or newly collected samples, (4) evaluation in a clinical trial, (5) implementation in clinical practice, and (6) proving the cost-effectiveness of the validated biomarker. The majority of LN urine biomarker studies to date have focused upon step one to three of this process.

3 The importance of assessing all novel biomarkers in children as well as adults

Juvenile and adult onset SLE differ in many ways. Juvenile onset disease is associated with more severe disease phenotype, including more renal involvement [1,17-21] and damage than in adult counterparts [17]. Compared with adult onset (18-50 years) and late onset SLE (>50 years old), juvenile onset patient have been shown to be at highest risk of renal failure and mortality [22]. Approximately 10% of children with proliferative nephritis progress to end-stage renal disease within 5 years [23], with irreversible renal damage remaining as one of the most common long-term consequences seen in JSLE [24]. It is anticipated that the differences in LN severity between juvenile and adult onset SLE populations may bear influence on the level of biomarkers reflecting the degree of renal injury within such populations. Urine biomarkers which are derived from plasma proteins may also show differences in their levels due to age dependent differences in plasma levels of the given protein. Childhood specific biomarker discovery and validation studies are therefore

important to explore these issues and in view of the fact that children tend to have fewer comorbidities (e.g. diabetes, cardiovascular disease or hypertension) which can confound the results of urine biomarker studies. Consequently, it may be that a biomarker is useful in a paediatric but not an adult SLE population, or vice versa. This may account for some of the differences in proteins identified from paediatric and adult SLE urine proteomic studies [25-27]. In light of such observations it has been proposed that all biomarker studies should be concurrently carried out on children as well as adults with SLE [28].

4 Why urine?

In LN, urine is increasingly becoming recognized as the most useful and desirable medium for biomarker discovery due to the non-invasive nature of sample collection and its ability to reflect kidney damage, given its close proximity to native renal cells. Plasma and serum are more complex sample types which are in contact with multiple organs and therefore less likely to yield organ specific biomarkers. The smaller number of core proteins in urine than plasma / serum (approximately 2000 vs. 10,000) also make urine a better medium for harvesting biomarkers [29,30].

Under physiological conditions, a relatively small amount of protein is excreted into the urine due to the highly efficient glomerular filtration barrier which consists of fenestrated endothelium, the collagenous glomerular basement membrane, and podocytes, with their interdigitating foot processes and slit diaphragms. These three layers restrict movement of proteins into the urine on the basis of their molecular weight, size and electrical charge. In glomerular diseases such as LN, this barrier is disrupted leading to leakage of plasma / serum proteins alongside secretion of specific proteins reflective of the inflammatory state and kidney damage [31]. The pathogenesis of LN is known to involve multiple inflammatory cells, cytokines, chemokines, adhesion molecules and their receptors. Efforts to identify urinary biomarkers to date have related to specific candidate biomarkers implicated in the pathogenesis of LN or hypothesis free biomarker screens (e.g. using proteomic techniques). In the next section, developments in biomarkers for LN will be reviewed, highlighting those that have gone through validation in independent patient cohorts and are of particular relevance to children.

5 Urine biomarkers relating to the pathophysiology of LN

5.1 Inflammatory cells as urine biomarkers

The immune cells known to infiltrate the kidney in LN are known to comprise of T cells, macrophages, B cells and plasma cells [32-34]. Urinary cells have been investigated as non-invasive biomarkers of the inflammatory renal environment, with their relationship to LN outcome, therapeutic response or future flares currently under investigation. The specific origin of urinary immune cells is unknown but is speculated to relate to peri-glomerular, peritubular or interstitial infiltrates. In a recent study of 19 SLE patients with active LN and 55 SLE patients without LN using flow cytometry based cell quantification; urinary T cell subsets, B cells and macrophage numbers were significantly higher in active LN patients. Urinary T cell sub-sets showed excellent distinction between patients with active LN and non-LN SLE patients (CD8⁺ T cells, area under the curve (AUC) of 1.000 and CD4⁺ T cells AUC of 0.9969). CD14⁺ macrophages performed slightly less well (AUC = 0.9066), and CD19⁺ B cells were only moderately elevated, failing to reach these high standards of differentiation between patient groups (AUC = 0.7823) [35]. The same group have previously shown that high urinary CD4⁺ T cells numbers were observed in patients with proliferative

LN, and that over time, normalization of urinary CD4 T cell counts was associated with lower disease activity and better renal function. Persistence or an increase in urinary T cell numbers associated with higher total SLE disease activity index (SLEDAI) scores, and poorer renal outcomes in terms of serum creatinine and proteinuria [36]. These results have been confirmed by a further group who found urinary CD4⁺ and CD8⁺ T-cell counts to discriminate between active and inactive LN (AUC 0.92 and 0.93, respectively) [37], and to decrease significantly in response to treatment [35].

Long-lived plasma cells (CD138+) are capable of continually secreting autoantibodies. These cells live in chronically inflamed tissues like the kidneys in addition to the bone marrow/spleen. Urinary free light chains (FLCs) are synthesised by such cells with the total urinary FLC levels correlating with the number of CD138+ long-lived plasma cells within the kidney and International Society of Nephrology / Renal Pathology Society (ISN/RPS) class III/IV LN [38]. Monitoring of urinary immune cells as biomarkers is limited by the relatively large volume of urine required to get enough cells for analysis (approximately 100mls as opposed to 20-200µl in many immune-assays). The urine also needs to be fresh and analysed within six hours of voiding [35]. In the future, measurement of markers associated with these cells may provide a simpler proxy for inflammatory cell numbers, and be more suited for paediatric studies.

5.2 Cytokines, chemokines and their receptors as urine biomarkers

Cytokines, chemokines and their receptors play an important role in the pathogenesis of LN. This has led to a variety of studies testing whether they may be used as potential urinary biomarkers for LN. Multiplex bead assays have made it possible to simultaneously screen for multiple cytokines in a single sample, saving precious patient samples and time.

5.2.1 Monocyte chemoattractant protein-1

Monocyte chemoattractant protein-1 (MCP-1) is one of the most extensively investigated urine biomarkers in LN. It is a leucocyte chemotactic factor, which acts to recruit inflammatory cells to infiltrate the kidney in LN, leading to inflammation and tissue injury [39]. Increased expression of MCP-1 has been demonstrated by immunohistochemistry and in situ hybridization in endothelial cells, renal epithelial cells and infiltrating mononuclear cells present in the tubulointerstitial region of the kidney in LN [40]. There is also a correlation between glomerular expression of MCP-1 and more severe histological classes of LN (class III and IV LN), correlating with poor renal prognosis [41]. A large number of paediatric and adult cross-sectional studies have consistently demonstrated that urinary levels of MCP-1 are elevated in patients with active LN, as compared to controls (those with inactive LN and / or healthy controls) [42-49]. Although MCP-1 is associated with renal involvement in SLE, it is also elevated in other types of glomerulonephritis [50].

In a JSLE study, Watson et al [51], examined urinary MCP-1 levels in 64 JSLE patients longitudinally, demonstrating MCP-1 to be an independent predictor for active renal disease at the time of the current review, and over time, low urinary MCP-1 levels were an excellent predictor of future renal disease improvement (AUC: 0.81; p=0.013). In an adult SLE longitudinal study, Rovin et al [45] demonstrated that urinary MCP-1 levels were significantly higher during renal as opposed to non-renal flares, increasing 2-4 months before a LN flare. Patients who responded to treatment showed a decrease in urinary MCP-1 levels over several months, whereas non-responders displayed persistently elevated MCP-1 levels. MCP-1 levels were also demonstrated to be higher in patients with proliferative LN (WHO class III/IV) as opposed to membranous (class V) nephritis. A further longitudinal study of 40

adult SLE patients supports these results, with urinary MCP-1 levels falling in responders, remaining elevated in non-responders and correlating with histological severity [52]. Of note, an adult SLE study including 136 patients found urinary MCP-1 levels to be no better than anti-dsDNA antibody or C3 at differentiating renal vs. non-renal SLE flares [53]. A further study by Tian et al [54] showed that MCP-1 was unable to predict the occurrence of a LN flare in advance.

MCP-1 antagonists have been shown to ameliorate lupus nephritis in MRL-(Fas)lpr autoimmune prone mice [55], and to permit a 75% reduction in the dose of cyclophosphamide required to control diffuse proliferative LN in such mice [56]. MCP-1 antagonists have also been investigated in early phase type 2 diabetes [57] and post-traumatic neuralgia [58] trials but are not currently being investigated in LN. See Table 1 for a summary of the evidence relating to MCP-1 in children.

5.2.2 Neutrophil gelatinase associated lipocalin

Urinary neutrophil gelatinase associated lipocalin (NGAL) has also been widely investigated in LN. It is a member of the lipocalin family of carrier proteins that is expressed by many cell types including neutrophils and renal tubular epithelial cells. It is responsible for cellular iron transport, apoptosis, bacteriostasis and tissue differentiation, and is implicated in the growth and differentiation of epithelial cells [59]. NGAL is constitutively expressed at low levels in the kidneys [60], and is up-regulated in response to acute renal injury in responses to inflammation, ischemia and infection [61-65]. It has been shown to be a useful non-invasive marker of acute kidney injury following cardiopulmonary bypass surgery in children [66], and is predictive of the need for dialysis in diarrhea-associated hemolytic uremic syndrome and renal graft rejection [61,67].

The first paediatric urinary NGAL study was carried out by Brunner et al [68] in a small cohort of 35 JSLE patients. They reported higher levels of urinary NGAL in JSLE compared to juvenile idiopathic arthritis (JIA) patients. NGAL levels were strongly to moderately correlated with renal SLEDAI defined disease activity and Systemic Lupus Collaborating Clinics (SLICC) defined damage, but not with extra-renal disease activity. Subgroup analysis showed NGAL levels to be highly sensitive and specific for identifying JSLE patients with biopsy-proven nephritis. In a further study, they found the combination of NGAL together with MCP-1 and creatinine clearance to be good for identifying LN chronicity (AUC 0.83) [69]. In an independent Egyptian paediatric cohort including 35 JSLE patients, urinary NGAL was shown to correlate with the renal SLEDAI score and be predictive of class III and IV LN with 91% sensitivity and 70% specificity [70]. Pitashny et al [71] demonstrated urinary NGAL levels to be significantly higher in LN than non-LN patients in a cohort of 70 adult SLE patients. Urinary NGAL levels correlated significantly with renal but not with extra-renal SLEDAI scores. 24 hour urinary NGAL excretion has been shown to be a potential biomarker of renal damage in adult SLE patients, correlating with serum creatinine and creatinine clearance but not the SLEDAI score [72].

NGAL has also been investigated in two paediatric longitudinal studies, where it has been demonstrated to be predictive of LN flare [51,73]. Suzuki et al [73] studied 85 JSLE, 30 JIA patients, and 50 HC's. They found plasma and urinary NGAL levels to be increased in JSLE patients compared to controls, with urinary NGAL being significantly associated with worsening of renal disease. A subsequent paper reporting ongoing longitudinal follow-up (≥ 3 follow-up visits) within this cohort, described urinary NGAL levels as increasing by up to 104%, up to 3 months before worsening of LN [74]. Watson et al [51], demonstrated urinary

NGAL to be a good predictor of worsening renal disease activity (AUC 0.76; $p=0.04$) over time in a study involving 64 JSLE patients. Similarly, in an adult SLE study which included the exploratory Einstein Lupus Cohort and a validation cohort from University College London, urinary NGAL levels were found to rise 3-6 months before renal flare and to perform better than anti-dsDNA antibody for prediction of renal flare [75]. However, in contrast to the above, a longitudinal study involving 107 adult SLE patients was unable to identify an association between urinary NGAL and any measure of LN disease activity [76]. These conflicting results may be explained by differences in the timing of the sample and the outcome measures used. See Table 1 for a summary of the evidence relating to NGAL in children.

5.2.3 Vascular cell adhesion molecule-1

Vascular cell adhesion molecule-1 (VCAM-1) has not been investigated in paediatric urinary biomarker studies to date, and warrants further investigation in this population. It is an adhesion molecule and member of the immunoglobulin superfamily, which interacts with integrins, supporting tethering and adhesion of leukocytes to endothelial cells and migration into organs such as the kidney. Wu et al [77], demonstrated that urinary levels of VCAM-1 correlate well with urine protein levels and disease activity scores in three murine lupus nephritis models. They extended their work to compare urine samples from 38 SLE patients, 15 normal controls and six rheumatoid arthritis (RA) control patients. SLE patients displayed significantly higher urinary VCAM-1 levels than controls, with LN patients exhibiting the highest VCAM-1 levels. Urinary VCAM-1 levels also correlated with urine protein to creatinine ratios and renal SLEDAI score.

Several other small cross-sectional studies have since looked at urinary VCAM-1 in human LN. Molad et al [78], looked at 24 SLE patients compared to HC's, showing urinary VCAM-1 to be significantly increased in the SLE patients, and to correlate with SLEDAI, low C3, creatinine clearance and albuminuria. Abd-Elkareem et al [79], studied 50 SLE patients (30 active LN, 20 no LN) and found elevated urinary VCAM-1 in class III, IV and V LN but not in class I/II, or non LN SLE patients. Howe et al [80], also showed urinary VCAM-1 to be significantly increased in active versus inactive LN in 121 SLE patients (33 with active LN). More recently, Singh et al [43], found VCAM-1 to discriminate between active and inactive LN (AUC 0.92), correlating positively with the renal pathology activity index and the presence of class IV LN. In a longitudinal study of 107 SLE patients followed for up to eight clinic visits, urinary VCAM-1 levels were shown to correlate with renal SLICC score, urine protein/creatinine ratio and physicians global assessment, but not renal histology [76].

5.2.4 Tumor necrosis factor-like weak inducer of apoptosis

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a soluble cytokine that is mainly produced by leukocytes, but also by resident renal cells, leading to elevated TWEAK expression within the kidney and urine of adults with lupus nephritis [81,82]. Expression of Fibroblast growth factor-inducible 14 (Fn14), the TWEAK signaling receptor, is rapidly unregulated in context of tissue injury, autoimmune / inflammatory diseases, and has been shown to be present on podocytes, endothelial, mesangial and tubular cells [82]. TWEAK / Fn14 signaling mediates a variety of physiological processes, including cellular proliferation, survival, differentiation, migration, angiogenesis, induction of cell death, up-regulation of pro-inflammatory mediators and chemoattractants. The TWEAK/Fn14 pathway is felt to promote local tissue regeneration and repair after acute injury but conversely, is also involved in tissue damage and pathological tissue remodeling in diseased end organs in the context of excessive or persistent Fn14 up-regulation [83,84]. Of note, blocking TWEAK/Fn14 interaction in murine inflammatory kidney disease leads to improvement in disease [84] and

Fn14 deficiency in a lupus prone mouse strain has been shown to ameliorate the diseases clinical phenotype [85].

Substantial evidence has accumulated for the role of urinary TWEAK as a biomarker for LN in adult SLE patients. In a cross-sectional study of 83 adult SLE patients, Schwartz et al [86], found urinary TWEAK levels to be significantly higher in patients with active LN vs. non-LN SLE patients, with TWEAK levels being higher during renal vs. non-renal flares and correlating with the renal SLEDAI score. Longitudinal follow-up of a subgroup of these patients, within a larger multicenter cohort, found urinary TWEAK levels were significantly higher during a renal flare than 4-6 months prior to/following a flare. A linear mixed-effects model showed a significant association between urinary TWEAK levels and disease activity over time. Urinary TWEAK levels were again higher in LN patients than non-LN SLE patients and also controls (diabetes related kidney disease, hypertension, RA or osteoarthritis). There was no significant association between TWEAK and LN histological classes [81]. Two subsequent cross-sectional studies looking at urinary TWEAK have demonstrated significantly higher TWEAK levels in adult SLE patients with active LN compared to those with no nephritis [44,87]. Further investigation in children and young people with SLE is warranted.

5.2.5 IL-6

IL-6 has not been investigated in a paediatric study to date. Two small adult SLE studies have suggested a role for IL-6 as a urinary biomarker for LN. The first included 29 patients with active LN and showed IL-6 levels to be higher in those with WHO class IV LN on biopsy than other classes [88]. A second study of 27 SLE patient and 17 HC's also found urinary IL-6 to be higher in active LN, compared to inactive LN and HC's [89]. However, in a larger study comparing urinary IL-6 in 143 patients with SLE, 128 with a positive anti-nuclear antigen (ANA, but <3 ACR criteria) and 73 HC's, IL-6 was high in the first two groups of patients, with no difference seen between SLE patients with / without LN [90].

5.2.6 Other chemokines and their receptors

Interferon- γ -inducible protein 10 (IP-10) is a chemokine produced by monocytes, endothelial cells and fibroblasts in response to IFN- γ . IP-10 promotes migration into the kidney of T-cells expressing the IP-10 receptor (Chemokine receptor 3, CXCR3), and an increase in CXCR3+CD4+ T cells has been demonstrated in LN kidney tissue and urine, correlating with disease activity [91]. IP-10 has also been shown to promote mesangial cell proliferation in adults with proliferative glomerulonephritis [92], with tubulo-interstitial IP-10 expression decreasing in serial biopsies where a LN patient changes from having proliferative / mixed nephritis to membranous nephropathy [93]. Avihingsanon et al [94], evaluated urinary mRNA levels of IP-10 and CXCR3, demonstrating that urinary mRNA levels of IP-10 and CXCR3 were significantly higher in class IV LN compared with classes II, III and V. A significant reduction in IP-10 and CXCR3 mRNA level was seen in patients who responded to treatment, whereas levels remained elevated in treatment resistant patients. Abujam et al [53], assessed urinary IP-10 and MCP-1 levels in the urinary supernatant of 138 adult SLE patients, demonstrating a significant difference in the levels of both biomarkers between active LN, active non-renal SLE patients and HC's. In ROC analysis, MCP-1 out performed IP-10 in its ability to identify active LN (AUC 0.78 vs. 0.68 respectively). Within a paediatric study, no difference in urinary supernatant IP-10 levels could be detected between active LN, JSLE non-LN patients or HC's [42], emphasizing the need to examine urine biomarkers in both adult and paediatric studies as differences may exist.

Chemokine (C-X-C motif) ligand 16 (CXCL16), is a surface bound and soluble chemokine produced by T-cells / dendritic cells under the control of IFN- γ /TNF- α . Urinary CXCL16 has been shown to discriminate adult patients with active LN from other SLE patients with an excellent AUC of 0.934 [77]. Given the potential role for chemokines and their receptors in the pathogenesis on LN, and as biomarkers for LN, further investigation of is required, especially within JSLE populations. RANTES (regulated on activation, normal T cell expressed and secreted) is a chemokine which is involved in T cell recruitment to inflamed sites. In adult patients with diffuse proliferative LN, urinary RANTES has been shown to be significantly higher during episodes of flare [54]. No evidence relating to urinary CXCR3, CXCL16 or RANTES is available in JSLE.

	Patients	Study design	Outcome	Ref
MCP-1	52 in-active LN, 8 active LN, 20 HC's	Cross-sectional Renal BILAG defined LN	Significantly higher urinary MCP-1 concentrations in active LN than patients with in-active renal disease or HC's.	[42]
	12 in-active LN, 13 active LN	Cross-sectional Biopsy defined LN	Significantly higher urinary MCP-1 concentrations in active LN than patients with in-active renal disease or HC's.	[46]
	15 active LN, 15 in-active LN, 15 never had LN, 15 HC's	Cross-sectional Biopsy defined LN	Significantly higher urinary MCP-1 concentrations in active LN than patients with in-active renal disease, those who have never had LN or HC's.	[49]
	26 JSLE patients aged ≤ 18 years, 50 SLE patient >18 years old. All active LN patients within 2 months of renal biopsy.	Cross-sectional biomarker panel Biopsy defined LN	<ul style="list-style-type: none"> MCP-1+AGP+CP+ protein:creatinine ratio = good for detecting LN histological activity (AUC 0.85). MCP1+ AGP+TF+CrCl+C4 = fair for membranous LN detection (AUC 0.75). MCP-1 +NGAL + Creatinine = good test for LN chronicity (AUC 0.83). 	[69]
	47 JSLE patients at the time of renal biopsy.	Cross-sectional biomarker panel Biopsy defined LN	National Institute for Health Activity Index status predicted by MCP-1, NGAL, ceruloplasmin, adiponectin and KIM-1, Hemopexin in combination, with $>92\%$ accuracy.	[95]
NGAL	12 active LN, 23 no LN, 8 JIA controls	Cross-sectional biomarker panel SLEDAI-2K defined LN (score >0 on the renal domain)	Significantly higher urinary NGAL concentrations in active LN, than in-active/no renal disease or JIA controls. NGAL levels not correlated with extra-renal disease or damage. NGAL levels $>0.6\text{ng/mg}$ creatinine were 90% sensitive and 100% specific for identifying JSLE patients with biopsy proven LN.	[68]
	26 active LN, 59 inactive LN, 30 JIA, 50 HC's	Cross-sectional and longitudinal (52/85 JSLE patients with ≥ 1 follow-up visit)	Significantly higher urinary NGAL levels in JSLE patients vs. controls. Moderate correlation of urinary NGAL with SLEDAI-2K defined renal diseases	[73]

	SLEDAI-2K defined LN (score >0 on the renal domain)	activity ($r=0.4$, $p<0.008$). Urinary NGAL not extra-renal SLEDAI scores. Longitudinally, urinary NGAL levels increased significantly with worsening of renal activity.
22 active LN, 11 inactive LN	Cross-sectional Biopsy defined LN	Significantly higher urinary NGAL concentrations in active LN than inactive LN and HC's. Urinary NGAL predictive of class III and IV LN with 91% sensitivity and 70% specificity. [70]
26 JSLE patients aged ≤ 18 years, 50 SLE patient >18 years old. All active LN patients within 2 months of renal biopsy.	Cross-sectional biomarker panel Biopsy defined LN	NGAL + MCP-1 + Creatinine = good test for LN chronicity (AUC 0.83). [69]
47 JSLE patients at the time of renal biopsy.	Cross-sectional biomarker panel Biopsy defined LN	National Institute for Health Activity Index status predicted by MCP-1, NGAL, ceruloplasmin, adiponectin and KIM-1, Hemopexin in combination, with >92% accuracy. [95]
111 JSLE patients with 365 follow-up episodes.	Longitudinal, at least 3 study visits. BILAG, and SLEDAI-2K defined LN	Urinary NGAL levels increased by an average of 70-104%, up to 3 months before worsening of LN. ROC analysis for ability of urinary NGAL to predict worsening LN gave an AUC of 0.78 when using SLEDAI-2K renal score as the external standard, or 0.80 when using the renal BILAG score. [74]

Table 1: Summary of evidence for cytokines, chemokines and their receptors as urine biomarkers in children. MCP-1 = monocyte chemoattractant protein-1, LN = lupus nephritis, HC's = healthy controls. JIA = juvenile idiopathic arthritis. BILAG = British Isles Lupus Assessment Group score, AGP = α -1 acid glycoprotein, TF = transferrin, CrCl = creatinine clearance, C4 = complement factor 4, AUC = area under the curve, NGAL = neutrophil gelatinase associated lipocalin, KIM-1 = kidney injury molecule 1, SLEDAI-2k = SLE disease activity index.

6 Proteomic based urine biomarker analysis

The normal urinary proteome contains a small but discrete amount of proteins. In pathological situations the urinary proteome can provide information regarding damage to all segments of the nephron, underscoring the physiological and biological processes taking place. There are different proteomic approaches which present different advantages and disadvantages. The more traditional separation of proteins with two-dimensional gel electrophoresis followed by mass spectrometry (2D-electrophoresis-MS) is labor intensive, may show poor reproducibility and requires a large amount of protein. It has a narrow dynamic range and cannot detect small (<10kDa), large (>150 kDa), hydrophobic or low

abundance proteins [96]. Liquid chromatography coupled to mass spectrometry (LC-MS) can be automated, is less time consuming, uses lower sample volumes and displays better sensitivity for smaller or hydrophobic proteins than 2DE-MS.

Surface-enhanced laser desorption/ionization time of flight (SELDI-TOF) technology uses protein-chip arrays coupled to a TOF mass spectrometer. These chips feature different surface binding properties (hydrophilic or hydrophobic materials, anionic or cationic, lectin, or antibody affinity reagents) leading to the binding of different proteins or peptides depending upon their properties. SELDI-TOF is widely used as it is high throughput and an easy to use technique that can be automated. It uses very small sample volumes, does not require pre-treatment of the sample and is sensitive for detection of low molecular weight proteins. SELDI-TOF has been widely used in LN but has two main disadvantages. Firstly, it identifies patterns of protein expression rather than specific proteins, and requires subsequent chromatographic enrichment and protein sequencing by capillary liquid chromatography-nanospray tandem mass spectrometry (LC/MS/MS), or on-chip protein sequencing using an LC/MS/MS system integrated with the SELDI-TOF mass spectrometer. The latter technique is limited to specific proteins, influencing the ability to undertake hypothesis free proteomic screening [96,97]. Secondly, intra / inter-assay coefficients of variation for protein peak abundance and intensities are approximately 20%, making the technique semi-quantitative, and requiring validation by another method [97-99]. Advancements in proteomics have provided considerable insight into the LN human urine proteome, and in this section, we will review the insights gained from paediatric and adult urine proteomic studies.

6.1 Adult proteomic studies

One of the earliest LN urinary proteomic studies by Mosley et al [100] used SELDI-TOF, identifying two proteins with masses of 3340 and 3980 which distinguished active from inactive LN, each with 92% sensitivity and specificity. This study featured a limited prospective longitudinal component including six patients, showing these proteins to predict both relapse and response to treatment earlier than traditional clinical markers. Using 2D-electrophoresis in 16 patients with LN, focal segmental glomerulosclerosis (FSGS), diabetic and membranous nephropathy, Varghese et al [25] used patterns of protein abundance to train an artificial neural network to create a prediction algorithm for identification of each disease. In an external validation set of 16 patients, the artificial neural network was found to be best for LN identification with a sensitivity of 86%, specificity of 89% and AUC of 0.84. Mass spectrometry was used to determine the identity of the proteins which included α 1-acid-glycoprotein (AGP), transferrin (TF), zinc α -2-glycoprotein (ZA2G), α -1- microglobulin, α -1-antitrypsin, plasma retinol binding protein (RBP), haptoglobin, complement factor B, transthyretin, hemopexin and albumin. The same group went on to undertake a complementary study using a similar approach (2D-electrophoresis followed by mass spectrometry, artificial neural network) to differentiate ISN/RPS LN classes using urine from 20 patients immediately before renal biopsy. The sensitivity and specificity of the different combinations for the ISN/RPS classes was class II 100%, 100%; III 86%, 100%; IV 100%, 92%; and V 92%, 50%. The 50% class V LN specificity was due to inclusion of patients with mixed class III, IV, V. These patients were correctly identified as having class III or IV disease which is more clinically appropriate. The top two proteins contributing most to the tests sensitivity were found to be AGP and α -1 microglobulin [101].

Zhang et al [102] subsequently sought to screen the low molecular weight proteome (<20kDa) in samples taken at baseline, pre-flare, flare, and post-flare by fractionating the urine to remove proteins larger than 30 kDa, and then spotting them onto weak cation

exchanger protein chips for analysis by SELDI-TOF MS. 19 patients were included with class III (n=5), class IV (n=11), or class V (n=3) LN. 27 protein ions were found to be differentially expressed between specific flare intervals. Using on-chip peptide sequencing by integrated tandem mass spectrometry a 20 amino acid isoform of Hepcidin and an albumin fragment (N-terminal region) were found to be increased 4 months pre-flare and returned to baseline at the time of renal flare, whereas a 25 amino acid isoform of Hepcidin decreased during a renal flare and returned to baseline 4 months post-flare (marker of treatment response). They also found α -1-antitrypsin to be increased at the time of flare.

Somparn et al [26] undertook 2D electrophoresis on samples from 5 active and 5 in-active LN patients, revealing 16 protein spots whose levels differed significantly between the groups (serotransferrin, AGP, alpha-2-HS glycoprotein, haptoglobin, alpha-1-antitrypsin, albumin, ZA2G (3 isoforms), immunoglobulin kappa chain (3 forms), RBP-4, beta-2-microglobulin, transthyretin and prostaglandin-H2-D isomerase (PGDS)). They choose to validate two of the markers; ZA2G (due to the magnitude of its change) and PGDS (because of its presence only in active LN), by ELISA in 30 active LN, 26 inactive LN, 14 non-LN glomerular diseases and 8 HC's. Urinary ZA2G levels significantly differentiated patients with active and in-active LN but were also elevated in patients with non-LN glomerular diseases. Urinary PGDS was only significantly elevated in active LN and is therefore thought to represent a LN specific biomarker.

Paediatric proteomic studies

Only two urinary proteomic studies have been carried out to date, both by Suzuki et al [27,103] in North American JSLE patients. In the first, SELDI-TOF-MS was used for proteomic profiling in 32 JSLE patients and 11 JIA patients. They identified a urinary proteomic signature consisting of eight proteins which displayed significantly higher peak intensities in patients with LN compared with controls or SLE patients without nephritis. These peaks had mass-to-charge ratios of 2.76, 22, 23, 44, 56, 79, 100, and 133. There was no significant difference in biomarker peak intensities between distinct WHO LN classes. The 22, 23, 44, 79, and 100 kDa peak were strongly correlated with renal disease activity as defined by the SLEDAI-2k score [103].

In the second study, surface-enhanced or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was used to identify TF, ceruloplasmin (CP), AGP, lipocalin-type prostaglandin-D synthetase (L-PGDS), albumin and albumin-related fragments as the proteins contained within the LN urinary protein signature.

Immunonephelometry or ELISA was then used to serially assess the ability of this protein signature to monitor LN disease activity over time in 98 JSLE patients and 30 JIA controls. All proteins were significantly higher in children with SLE than JIA. Individual urinary biomarkers displayed fair to good ability to identify SLEDAI or BILAG defined active LN (AUC values between 0.68-0.81), with the AUC improving to 0.85 when all of the biomarkers were considered together. Urinary levels of TF, AGP and L-PGDS increased significantly 3 months before the clinical (SLEDAI based) diagnosis of worsening LN. However, significant increases in AGP and L-PGDS levels over time were also demonstrated in patients with stable active LN, improved LN (AGP) and inactive LN (LPGDS) [27], highlighting that further prospective studies are required to improve our understanding of the relationship of these biomarkers to disease activity over time. There is clearly overlap between some but not all biomarkers identified in adult and paediatric studies, highlighting the importance of undertaking biomarker studies in both patient groups rather than extrapolating between them.

6.2 Validation of proteomic results

The validity of previously established proteomic biomarkers must be assessed on separate groups of patients to provide independent verification of the findings and evaluation of biomarker sensitivity, specificity and predictive capabilities. This validation may either take the form of an independent proteomic study or through use of other protein binding techniques e.g. ELISA or multiplex assays, to quantify individual or combinations of biomarkers in a larger group of patients. Such techniques are quicker, usually highly sensitive and specific for the marker of interest, and readily available within many clinical or research laboratories. Table 2 lists the proteins identified in LN proteomic studies that have undergone internal or external validation using additional methods for protein quantification \pm further proteomic techniques. Figure 1 also provides an overview of the evidence relating to protein urine biomarkers to date, and how they relate to the different clinical scenarios faced during the natural course of LN progression.

Protein	Original proteomic study	Validation Studies	
		Proteomic	Other methods / techniques
Biomarkers identified in ≥2 proteomic studies and validated using other methods			
AGP	Oates [101]	Varghese [25] Suzuki [103]	Suzuki [27], 98 JSLE, ELISA's, serially assessed AGP, TF, CP, LPGDS. AUC of 0.85 for active LN identification when all biomarkers combined. Brunner [69], 76 SLE patients, ELISA's. AGP+MCP1+CP+protein:creatinine ratio = good for detecting LN histological activity (AUC 0.85). AGP+MCP-1+TF+CrCl+C4 = fair for membranous LN detection (AUC 0.75). Watson [42], 60 JSLE patients, ELISA. Urinary AGP significantly elevated in active LN.
TF	Varghese [25]	Suzuki [103]	Suzuki [27] – as described above Brunner [69] – as described above
ZA2G	Varghese [25]	Somparn [26]	Somparn [26], ELISA, 30 active LN, 26 inactive, 14 non-LN kidney disease. ZA2G levels higher in active LN.
RBP-4	Varghese [25]	Somparn [26]	Sesso [104], 70 SLE patients, immunoenzymometric assay. RBP-4 significantly higher in active LN. Marks [105], 21 JSLE patients, 10 active LN, 11 inactive, ELISA. RBP levels significantly higher in active LN.
PGDS or LPGDS	Suzuki [103]	Somparn [26]	Suzuki [27] – as described above Somparn [26], ELISA, 30 active LN, 26 inactive LN, 14 non-LN kidney disease, 8 HC's, PDGS significantly elevated in active LN. Gupta [106] 28 SLE patients with active LN, 6 inactive SLE, 12 active non-renal disease and 19 HC's. ELISA. Significantly higher levels in active-LN. Levels fell in those responding to LN treatment and remained elevated in patients developed chronic kidney disease.
Biomarkers identified in a single proteomic study and validated using another technique			
Hemopexin	Varghese [25]	NA	Brunner [95], 47 active LN JSLE patients, ELISA. National Institute for Health Activity Index status predicted by NGAL, MCP-1, CP, adiponectin and KIM-1, Hemopexin in combination.
Hepcidin	Zhang [102]	NA	Mohammed [107], 30 active LN, 30 non-LN SLE patients and 30 HC's, ELISA. Hepcidin higher in active LN.
K-FLC	Somparn [26]	NA	Hanaoka [38], 43 SLE patients, Nephrometric assay. Both κ/λ FLC's increased in class III/IV LN vs I/II/IV.
β2MG	Somparn [26]	NA	Tsai [89], 15 active LN, 12 with in-active LN, ELISA. Levels did not differ between groups. Choe [108], 64 SLE patients, ELISA, significantly higher in patients with active LN.
CP	Suzuki [103]	NA	Suzuki [27] - as described above Brunner [69] - as described above, Brunner [95] - as described above
Angiostatin	Wu [109]	NA	Wu [109], 100 SLE, 24 CKD patients and 30 HC's. ELISA, angiostatin identified active AUC = 0.83

Table 2: Proteins identified in LN proteomic studies that have undergone validation using additional methods for protein quantification ± further proteomic techniques.

Abbreviations = AGP = α -1 acid glycoprotein. TF = transferrin. CP = ceruloplasmin, MCP-1 = monocyte chemoattractant protein. CrCl = Creatinine Clearance. ZA2G = Zinc α -2-glycoprotein. HC's = healthy controls. RBP= plasma retinol binding protein. PGDS = Prostaglandin-H2-D isomerase, alternative name LPGDS = Lipocalin- type prostaglandin-D synthetase. Hepcidin = 20 & 25 amino acid isoforms. K-FLC= κ free light chain. β 2MG = Beta-2-microglobulin. CKD = chronic kidney disease patients.

7 Origin / role of key proteins identified and validated in paediatric proteomic studies

It is interesting to consider the role and origin of proteins which have been identified in proteomic studies and validated extensively. AGP (also called Orosomucoid) belongs to the immunocalin family, a group of binding proteins which binds and transport small hydrophobic molecules and also has immunomodulatory functions. AGP is also one of the major acute phase proteins, which is mainly secreted by hepatocytes as part of the systemic response to inflammatory mediators (IL-1, IL-6, IL-8) or stressful stimuli such as physical trauma or bacterial infections. AGP production has also been reported in several tissues outside the liver including alveolar stimulated macrophages [110], human endothelial cells [111], cultured monocytes [112,113], resting and activated polymorphs [114,115]. L-PGDS is secretory protein of the lipocalin superfamily that acts as an enzyme responsible for the production of prostaglandin D2. It is produced in the brain by the choroid plexus or leptomeninges and is continuously secreted through cerebrospinal fluid into blood. L-PGDS is similar to albumin in chemical properties but is much smaller, allowing it to pass more readily through the glomerular capillary walls [116].

CP is involved in the metabolism of iron and carries the vast amount of circulating copper in the plasma [117]. TF is a metal binding protein with high affinity for iron, binding and moving it into cells and tissues. Iron is important to normal immune function, contributing to cell differentiation and growth. Alterations in iron homeostasis have been associated with several rheumatological and autoimmune disease [118]. Both CP and TF differ from albumin in terms of their molecular radii and isoelectric points, and have been shown to predict the onset of microalbuminuria at an earlier stage in conditions such as type 2 diabetes [119,120]. RBP-4 is mainly secreted by hepatocytes and adipose tissue, and also belongs to the lipocalin family. It is a carrier for retinol (vitamin A), delivering it to peripheral tissues, and urinary RBP-4 has been shown to be a biomarker for proximal renal tubule dysfunction [121]. Hemopexin is an acute phase reactant which is synthesized in the liver, binding and neutralizes pro-oxidant free heme, protecting the body from oxidative damage and preserving iron stores [122].

8 Metabolites

Metabolomics is a systems biology approach which investigates the overall metabolic activity of an individual, taking into account the influence of the genetic background and environment. Just as transcriptomics involves the study of gene expression, and proteomics the expression of proteins, metabolomics investigates the consequences of the activity of these genes and proteins, providing information on an individuals small molecule metabolite profile and unique chemical fingerprint [123]. To date there has been one small study looking at urinary metabolites in LN. This study included seven patients with class III/IV LN and seven with class V LN, utilising NMR spectroscopy based metabolic profiling. Significant differences were identified in citrate and taurine levels between class III/IV and V LN patients [124]. Currently there is no consensus on the best approach for normalisation of

metabolomics results from urine samples taking urinary dilution into account [125]. Further work is required extending these interesting analyses to larger patient cohorts, applying a normalisation factor and validating results using alternative techniques.

9 Conclusions - the future of urine biomarkers in LN

There have been an increasing number of promising urine biomarker studies over the last 10-15 years which have investigated a variety of biomarkers for LN. Early research into biomarker identification is becoming simpler through novel cutting edge technologies, which measure individual or combinations of biomarkers in miniscule patient samples. These data have provided insights into the pathophysiology and monitoring of LN but have not been translated into clinical practice, with the majority of studies concluding after the first or second phases of biomarker discovery. Moving such discoveries forward towards translation is complex and reliant upon studies which are carefully planned to avoid common pitfalls relating to sample size, accuracy of patient stratification over time, variation in the standard operating procedures for sample selection, collection, storage, handling, analysis and data interpretation. LN urine biomarker studies vary in terms of the outcome measures used to define active LN, with some studies relying upon composite disease activity measures (e.g. renal BILAG or SLEDAI) and others upon histological classification of LN (e.g. ISN/RPS classification, WHO criteria, National Institute for Health (NIH) activity, chronicity or tubular indices). Kidney biopsy is considered the gold standard test for LN, but unfortunately is also imperfect, relying on an invasive procedure for sampling and the subjective appearance of a few glomeruli in what can be a patchy disease.

The above methodological aspects and difficulties in LN urine biomarkers studies have impacted upon the perceived sensitivity, specificity, and predictive value of biomarkers thus far. Going forwards, it is important that the promising markers identified so far are further nurtured and internationally validated in adequately powered paediatric and adult SLE collaborative longitudinal studies, allowing us to move these discoveries towards clinical translation. Opportunities to include both paediatric and adult patients in urine biomarker studies should not be missed but considered integral to the development process, as is increasingly becoming the case in drug development. For such a study to be possible, the international community must assess and agree the measures which should be used to assess for active LN, with consideration as to whether more comprehensive validation is required of the disease activity measures for identification of active LN.

We must move from designing studies which do not only stratify patients as active / in-active LN but answer clinically important questions relating to the ability of biomarkers to predict a LN flare, identify active LN / evaluate its severity, determine response to a variety of treatments and assess for the presence of chronic renal damage over time. It has increasingly become clear that an individual biomarker will not provide optimal specificity and sensitivity in isolation, and that use of a combinatorial approach is of immense importance. Figure 2 shows a representation of the forecasted exciting future utility of urine biomarkers in LN monitoring and management. Our objective should therefore be the implementation of international collaborative efforts within paediatric and adult rheumatology communities for translating experimental findings into clinical trials, to make these ideals a reality.

Acknowledgements

This work was supported by the Alder Hey Children's Kidney Fund through a training fellowship (ES) [UOG10065 to ES], the UK Experimental Arthritis Treatment Centre for

Children, the National Institute for Health Research (NIHR) Alder Hey Clinical Research Facility. The funding bodies detailed above were not involved in the writing of the manuscript.

Figure Legends

Figure 1: Overview of the evidence relating to urine biomarkers to date and how they relate to distinct clinical questions in LN monitoring. Markers which are A) early predictors of flare, B) able to identify an active LN flare, C) used to evaluate flare severity, D) for identification of treatment non-responders, E) to identify chronic kidney damage. Urinary biomarkers shown in black are from paediatric studies, those in grey are from adult studies. NGAL = neutrophil gelatinase associated lipocalin. AGP = α -1 acid glycoprotein. TF = transferrin. CP = ceruloplasmin. LPGDS = Lipocalin- type prostaglandin-D synthetase. MCP1 = monocyte chemoattractant protein. VCAM-1 = vascular cell adhesion molecule 1. TWEAK = tumor necrosis like weak inducer of apoptosis. RBP= plasma retinol binding protein. Il-6 = interleukin 6. CXCL16 = Chemokine (C-X-C motif) ligand 16. RANTES = Regulated on Activation, Normal T Expressed and Secreted, ZA2G = Zinc α -2-glycoprotein. ISN/RPS = International Society of Nephrology / Renal Pathology Society classification. CrCl = Creatinine Clearance. K/L-FLC= kappa / lamda free light chains. IP-10 = Interferon gamma-induced protein 10. CXCR3 = Chemokine (C-X-C Motif) Receptor 3. NIH = national institute for health. UPUC = urine protein/creatinine ratio. KIM-1 = kidney injury molecule 1.

Figure 2: Future utility of urine biomarkers in LN monitoring and management. NGAL = neutrophil gelatinase associated lipocalin. AGP = α -1 acid glycoprotein. TF = transferrin. CP = ceruloplasmin. LPGDS = Lipocalin- type prostaglandin-D synthetase. VCAM-1 = vascular cell adhesion molecule 1. TWEAK = tumor necrosis like weak inducer of apoptosis. RBP= plasma retinol binding protein. Il-6 = interleukin 6. CXCL16 = Chemokine (C-X-C motif) ligand 16. RANTES = Regulated on Activation, Normal T Expressed and Secreted, ZA2G = Zinc α -2-glycoprotein. ISN/RPS = International Society of Nephrology / Renal Pathology Society classification. K/L-FLC= kappa / lamda free light chains. MCP1 = monocyte chemoattractant protein. IP-10 = Interferon gamma-induced protein 10. CXCR3 = Chemokine (C-X-C Motif) Receptor 3. CrCl = Creatinine Clearance. C4 = complement factor 4. NIH = national institute for health. UPUC = urine protein/creatinine ratio. KIM-1 = kidney injury molecule 1.

References

1. Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, Gardner-Medwin J, Wilkinson N, Riley P, Tizard J, Armon K, Sinha MD, Ioannou Y, Archer N, Bailey K, Davidson J, Baildam EM, Cleary G, McCann LJ, Beresford MW (2012) Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. *Arthritis Rheum* 64 (7):2356-2365
2. Tucker LB, Menon S, Schaller JG, Isenberg DA (1995) Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. *British Journal Rheumatology* 34 (9):866-872
3. Brunner HI, Gladman DD, Ibarñez D, Urowitz MD, Silverman ED (2008) Difference in Disease Features Between Childhood-Onset and Adult-Onset Systemic Lupus Erythematosus. *Arth & Rheum* 58 (2):556-562
4. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. *J Am Soc Nephrol* 15 (2):241-250
5. Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, Eddy A, Gladman D, Urowitz M, Hebert D, Silverman E (2002) Longterm followup of childhood lupus nephritis. *J Rheumatol* 29 (12):2635-2642
6. Greloni G, Scolnik M, Marin J, Lancioni E, Quiroz C, Zacarias J, De la Iglesia Niveyro P, Christiansen S, Pierangelo MA, Varela CF, Rosa-Diez GJ, Catoggio LJ, Soriano ER (2014) Value of repeat biopsy in lupus nephritis flares. *Lupus Sci Med* 1 (1):e000004. doi:10.1136/lupus-2013-000004
7. Touma Z, Urowitz MB, Ibanez D, Gladman DD (2014) Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. *J Rheumatol* 41 (4):688-697. doi:10.3899/jrheum.130005
8. Schwartz GJ, Haycock GB, Edelmann CM, Jr., Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. *Pediatrics* 58 (2):259-263
9. Ishizaki J, Saito K, Nawata M, Mizuno Y, Tokunaga M, Sawamukai N, Tamura M, Hirata S, Yamaoka K, Hasegawa H, Tanaka Y (2015) Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus. *Rheumatology (Oxford)* 54 (3):405-412. doi:10.1093/rheumatology/keu343
10. Alvarado AS, Malvar A, Lococo B, Alberton V, Toniolo F, Nagaraja HN, Rovin BH (2014) The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. *Lupus* 23 (8):840-847. doi:10.1177/0961203313518625
11. Moroni G, Quaglini S, Radice A, Trezzi B, Raffiotta F, Messa P, Sinico RA (2015) The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. *J Immunol Res* 2015:106904. doi:10.1155/2015/106904

12. Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, Clarke AE (1996) Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? *J Rheumatol* 23 (11):1891-1896
13. Steiman AJ, Gladman DD, Ibanez D, Urowitz MB (2010) Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. *J Rheumatol* 37 (9):1822-1827. doi:10.3899/jrheum.100007
14. Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K (2003) Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. *Annals of Rheumatic Disease* 62 (5):435-439
15. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramowicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. *Arthritis Rheum* 50 (12):3934-3940. doi:10.1002/art.20666
16. Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles C, Dominiczak A, Dylag T, Ehrich J, Egido J, Findeisen P, Jankowski J, Johnson RW, Julien BA, Lankisch T, Leung HY, Maahs D, Magni F, Manns MP, Manolis E, Mayer G, Navis G, Novak J, Ortiz A, Persson F, Peter K, Riese HH, Rossing P, Sattar N, Spasovski G, Thongboonkerd V, Vanholder R, Schanstra JP, Vlahou A (2012) Implementation of proteomic biomarkers: making it work. *Eur J Clin Invest* 42 (9):1027-1036. doi:10.1111/j.1365-2362.2012.02674.x
17. Tucker LB, Uribe AG, Fernandez M, Vila LM, McGwin G, Apte M, Fessler BJ, Bastian HM, Reveille JD, Alarcon GS (2008) Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). *Lupus* 17 (4):314-322
18. Tarr T, Derfalvi B, Gyori N, Szanto A, Siminszky Z, Malik A, Szabo AJ, Szegedi G, Zeher M (2015) Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. *Lupus* 24 (8):796-803. doi:10.1177/0961203314563817
19. Hoffman IE, Lauwerys BR, De Keyser F, Huizinga TW, Isenberg D, Cebecauer L, Dehoorne J, Joos R, Hendrickx G, Houssiau F, Elewaut D (2009) Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. *Ann Rheum Dis* 68 (3):412-415. doi:10.1136/ard.2008.094813
20. Martinez-Barrio J, Ovalles-Bonilla JG, Lopez-Longo FJ, Gonzalez CM, Montoro M, Valor L, Martinez LP, Nieto JC, Hinojosa-Davila MC, Bello N, Monteagudo I, Naredo E, Carreno L (2015) Juvenile, adult and late-onset systemic lupus erythematosus: a long term follow-up study from a geographic and ethnically homogeneous population. *Clin Exp Rheumatol* 33 (6):788-794
21. Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA, Group UJS (2016) Differences in disease phenotype and severity in SLE across age groups. *Lupus*. doi:10.1177/0961203316644333
22. Chen YM, Lin CH, Chen HH, Chang SN, Hsieh TY, Hung WT, Hsieh CW, Lai KL, Lan JL, Chen DY, Lan TH (2014) Onset age affects mortality and renal outcome of female systemic lupus erythematosus patients: a nationwide population-based study in Taiwan. *Rheumatology (Oxford)* 53 (1):180-185. doi:10.1093/rheumatology/ket330

23. Lee BS, Cho HY, Kim EJ, Kang HG, Ha IS, Cheong HI, Kim JG, Lee HS, Choi Y (2007) Clinical outcomes of childhood lupus nephritis: a single center's experience. *Pediatr Nephrol* 22 (2):222-231. doi:10.1007/s00467-006-0286-0
24. Marini R, Costallat LT (1999) Young age at onset, renal involvement, and arterial hypertension are of adverse prognostic significance in juvenile systemic lupus erythematosus. *Rev Rhum Engl Ed* 66 (6):303-309
25. Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS, Arthur JM (2007) Urine biomarkers predict the cause of glomerular disease. *J Am Soc Nephrol* 18 (3):913-922. doi:10.1681/ASN.2006070767
26. Somparn P, Hirankarn N, Leelahavanichkul A, Khovidhunkit W, Thongboonkerd V, Avihingsanon Y (2012) Urinary proteomics revealed prostaglandin H(2)D-isomerase, not Zn-alpha2-glycoprotein, as a biomarker for active lupus nephritis. *J Proteomics* 75 (11):3240-3247. doi:10.1016/j.jprot.2012.03.034
27. Suzuki M, Wiers K, Brooks EB, Greis KD, Haines K, Klein-Gitelman MS, Olson J, Onel K, O'Neil KM, Silverman ED, Tucker L, Ying J, Devarajan P, Brunner HI (2009) Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. *Pediatr Res* 65 (5):530-536. doi:10.1203/PDR.0b013e31819e4305
28. Watson L, Beresford MW (2013) Urine biomarkers in juvenile-onset SLE nephritis. *Pediatr Nephrol* 28 (3):363-374. doi:10.1007/s00467-012-2184-y
29. Wasinger VC, Zeng M, Yau Y (2013) Current status and advances in quantitative proteomic mass spectrometry. *Int J Proteomics* 2013:180605. doi:10.1155/2013/180605
30. Marimuthu A, O'Meally RN, Chaerkady R, Subbannayya Y, Nanjappa V, Kumar P, Kelkar DS, Pinto SM, Sharma R, Renuse S, Goel R, Christopher R, Delanghe B, Cole RN, Harsha HC, Pandey A (2011) A comprehensive map of the human urinary proteome. *J Proteome Res* 10 (6):2734-2743. doi:10.1021/pr2003038
31. D'Amico G, Bazzi C (2003) Pathophysiology of proteinuria. *Kidney Int* 63 (3):809-825. doi:10.1046/j.1523-1755.2003.00840.x
32. Giannakakis K, Faraggiana T (2011) Histopathology of lupus nephritis. *Clin Rev Allergy Immunol* 40 (3):170-180. doi:10.1007/s12016-010-8207-1
33. Caligaris-Cappio F, Bergui L, Tesio L, Ziano R, Camussi G (1985) HLA-Dr+ T cells of the Leu 3 (helper) type infiltrate the kidneys of patients with systemic lupus erythematosus. *Clin Exp Immunol* 59 (1):185-189
34. Boucher A, Droz D, Adafer E, Noel LH (1986) Characterization of mononuclear cell subsets in renal cellular interstitial infiltrates. *Kidney Int* 29 (5):1043-1049
35. Kopetschke K, Klocke J, Griessbach AS, Humrich JY, Biesen R, Dragun D, Burmester GR, Enghard P, Riemekasten G (2015) The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers. *Arthritis Res Ther* 17:94. doi:10.1186/s13075-015-0600-y
36. Enghard P, Rieder C, Kopetschke K, Klocke JR, Undeutsch R, Biesen R, Dragun D, Gollasch M, Schneider U, Aupperle K, Humrich JY, Hiepe F, Backhaus M, Radbruch AH, Burmester GR, Riemekasten G (2014) Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. *Ann Rheum Dis* 73 (1):277-283. doi:10.1136/annrheumdis-2012-202784
37. Dolff S, Abdulahad WH, Arends S, van Dijk MC, Limburg PC, Kallenberg CG, Bijl M (2013) Urinary CD8+ T-cell counts discriminate between active and inactive lupus nephritis. *Arthritis Res Ther* 15 (1):R36. doi:10.1186/ar4189

38. Hanaoka M, Gono T, Kawaguchi Y, Uchida K, Koseki Y, Katsumata Y, Kaneko H, Takagi K, Ichida H, Nitta K, Yamanaka H (2013) Urinary free light chain is a potential biomarker for ISN/RPS class III/IV lupus nephritis. *Rheumatology (Oxford)* 52 (12):2149-2157. doi:10.1093/rheumatology/ket108
39. Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. *J Interferon Cytokine Res* 29 (6):313-326. doi:10.1089/jir.2008.0027
40. Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, Takahashi Y, Sasaki T, Furuichi K, Segawa C, Hisada Y, Ohta S, Takasawa K, Kobayashi K, Matsushima K (1996) Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. *Kidney Int* 49 (3):761-767
41. Marks SD, Williams SJ, Tullus K, Sebire NJ (2008) Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. *Nephrol Dial Transplant* 23 (11):3521-3526. doi:10.1093/ndt/gfn270
42. Watson L, Midgley A, Pilkington C, Tullus K, Marks S, Holt R, Jones C, Beresford M (2012) Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. *Lupus* 21 (5):496-501. doi:10.1177/0961203311431249
43. Singh S, Wu T, Xie C, Vanarsa K, Han J, Mahajan T, Oei HB, Ahn C, Zhou XJ, Putterman C, Saxena R, Mohan C (2012) Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis. *Arthritis Res Ther* 14 (4):R164. doi:10.1186/ar3912
44. El-Shehaby A, Darweesh H, El-Khatib M, Momtaz M, Marzouk S, El-Shaarawy N, Emad Y (2011) Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. *J Clin Immunol* 31 (5):848-856. doi:10.1007/s10875-011-9555-1
45. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN (2005) Urine chemokines as biomarkers of human systemic lupus erythematosus activity. *J Am Soc Nephrol* 16 (2):467-473. doi:10.1681/ASN.2004080658
46. Marks SD, Shah V, Pilkington C, Tullus K (2010) Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis. *Pediatr Nephrol* 25 (11):2283-2288. doi:10.1007/s00467-010-1605-z
47. Kiani AN, Johnson K, Chen C, Diehl E, Hu H, Vasudevan G, Singh S, Magder LS, Knechtle SJ, Petri M (2009) Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. *J Rheumatol* 36 (10):2224-2230. doi:10.3899/jrheum.081112
48. Rosa RF, Takei K, Araujo NC, Loduca SM, Szajubok JC, Chahade WH (2012) Monocyte chemoattractant-1 as a urinary biomarker for the diagnosis of activity of lupus nephritis in Brazilian patients. *J Rheumatol* 39 (10):1948-1954. doi:10.3899/jrheum.110201
49. Ghobrial EE, El Hamshary AA, Mohamed AG, Abd El Raheim YA, Talaat AA (2015) Urinary monocyte chemoattractant protein-1 as a biomarker of lupus nephritis activity in children. *Saudi J Kidney Dis Transpl* 26 (3):507-515. doi:10.4103/1319-2442.157350
50. Kim MJ, Tam FW (2011) Urinary monocyte chemoattractant protein-1 in renal disease. *Clin Chim Acta* 412 (23-24):2022-2030. doi:10.1016/j.cca.2011.07.023
51. Watson L, Tullus K, Pilkington C, Chesters C, Marks SD, Newland P, Jones CA, Beresford MW (2013) Urine biomarkers for monitoring juvenile lupus nephritis: a prospective longitudinal study. *Pediatr Nephrol* 29 (3):397-405. doi:10.1007/s00467-013-2668-4
52. Singh RG, Usha, Rathore SS, Behura SK, Singh NK (2012) Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare. *Lupus* 21 (11):1214-1218. doi:10.1177/0961203312452622

53. Abujam B, Cheekatla S, Aggarwal A (2013) Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis. *Lupus* 22 (6):614-623. doi:10.1177/0961203313484977
54. Tian S, Li J, Wang L, Liu T, Liu H, Cheng G, Liu D, Deng Y, Gou R, Wan Y, Jia J, Chen C (2007) Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. *Inflamm Res* 56 (7):304-310. doi:10.1007/s00011-007-6147-x
55. Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer S, Vielhauer V, Klusmann S, Anders HJ (2007) Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. *J Am Soc Nephrol* 18 (8):2350-2358. doi:10.1681/ASN.2006121348
56. Kulkarni O, Eulberg D, Selve N, Zollner S, Allam R, Pawar RD, Pfeiffer S, Segerer S, Klusmann S, Anders HJ (2009) Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice. *J Pharmacol Exp Ther* 328 (2):371-377. doi:10.1124/jpet.108.142711
57. Di Prospero NA, Artis E, Andrade-Gordon P, Johnson DL, Vaccaro N, Xi L, Rothenberg P (2014) CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. *Diabetes Obes Metab* 16 (11):1055-1064. doi:10.1111/dom.12309
58. Kalliomaki J, Attal N, Jonzon B, Bach FW, Huizar K, Ratcliffe S, Eriksson B, Janecki M, Danilov A, Bouhassira D, Group APS (2013) A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. *Pain* 154 (5):761-767. doi:10.1016/j.pain.2013.02.003
59. Gwira JA, Wei F, Ishibe S, Ueland JM, Barasch J, Cantley LG (2005) Expression of neutrophil gelatinase-associated lipocalin regulates epithelial morphogenesis in vitro. *J Biol Chem* 280 (9):7875-7882. doi:10.1074/jbc.M413192200
60. Schwartz N, Michaelson JS, Putterman C (2007) Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. *Ann N Y Acad Sci* 1109:265-274. doi:10.1196/annals.1398.032
61. Trachtman H, Christen E, Cnaan A, Patrick J, Mai V, Mishra J, Jain A, Bullington N, Devarajan P, Investigators of the HUSPMCT (2006) Urinary neutrophil gelatinase-associated lipocalin in D+HUS: a novel marker of renal injury. *Pediatr Nephrol* 21 (7):989-994. doi:10.1007/s00467-006-0146-y
62. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P (2004) Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. *Am J Nephrol* 24 (3):307-315. doi:10.1159/000078452
63. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P (2003) Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. *J Am Soc Nephrol* 14 (10):2534-2543
64. Rubinstein T, Pitashny M, Putterman C (2008) The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/Lipocalin-2 as a biomarker for lupus nephritis. *Autoimmun Rev* 7 (3):229-234. doi:10.1016/j.autrev.2007.11.013
65. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A, Group NM-al (2009) Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis* 54 (6):1012-1024. doi:10.1053/j.ajkd.2009.07.020
66. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P (2005) Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. *Lancet* 365 (9466):1231-1238. doi:10.1016/S0140-6736(05)74811-X

67. Hollmen ME, Kyllonen LE, Inkinen KA, Lalla ML, Salmela KT (2011) Urine neutrophil gelatinase-associated lipocalin is a marker of graft recovery after kidney transplantation. *Kidney Int* 79 (1):89-98. doi:10.1038/ki.2010.351
68. Brunner HI, Mueller M, Rutherford C, Passo MH, Witte D, Grom A, Mishra J, Devarajan P (2006) Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. *Arthritis Rheum* 54 (8):2577-2584. doi:10.1002/art.22008
69. Brunner HI, Bennett MR, Mina R, Suzuki M, Petri M, Kiani AN, Pendl J, Witte D, Ying J, Rovin BH, Devarajan P (2012) Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. *Arthritis Rheum* 64 (8):2687-2697. doi:10.1002/art.34426
70. Hammad A, Mosaad Y, Elhanbly S, Youssef H, El Refaaey A, Elhusseini F, Bakr A (2013) Urinary neutrophil gelatinase-associated lipocalin as a marker of severe lupus nephritis in children. *Lupus* 22 (5):486-491. doi:10.1177/0961203313479419
71. Pitashny M, Schwartz N, Qing X, Hojaili B, Aranow C, Mackay M, Putterman C (2007) Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. *Arthritis Rheum* 56 (6):1894-1903. doi:10.1002/art.22594
72. Yang CC, Hsieh SC, Li KJ, Wu CH, Lu MC, Tsai CY, Yu CL (2012) Urinary neutrophil gelatinase-associated lipocalin is a potential biomarker for renal damage in patients with systemic lupus erythematosus. *J Biomed Biotechnol* 2012:759313. doi:10.1155/2012/759313
73. Suzuki M, Wiers KM, Klein-Gitelman MS, Haines KA, Olson J, Onel KB, O'Neil K, Passo MH, Singer NG, Tucker L, Ying J, Devarajan P, Brunner HI (2008) Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. *Pediatr Nephrol* 23 (3):403-412. doi:10.1007/s00467-007-0685-x
74. Hinze CH, Suzuki M, Klein-Gitelman M, Passo MH, Olson J, Singer NG, Haines KA, Onel K, O'Neil K, Silverman ED, Tucker L, Ying J, Devarajan P, Brunner HI (2009) Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. *Arthritis Rheum* 60 (9):2772-2781. doi:10.1002/art.24751
75. Rubinstein T, Pitashny M, Levine B, Schwartz N, Schwartzman J, Weinstein E, Pego-Reigosa JM, Lu TY, Isenberg D, Rahman A, Putterman C (2010) Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. *Rheumatology (Oxford)* 49 (5):960-971. doi:10.1093/rheumatology/kep468
76. Kiani AN, Wu T, Fang H, Zhou XJ, Ahn CW, Magder LS, Mohan C, Petri M (2012) Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. *J Rheumatol* 39 (6):1231-1237. doi:10.3899/jrheum.111470
77. Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, Mackay M, Aranow C, Putterman C, Mohan C (2007) Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. *J Immunol* 179 (10):7166-7175
78. Molad Y, Miroshnik E, Sulkes J, Pitlik S, Weinberger A, Monselise Y (2002) Urinary soluble VCAM-1 in systemic lupus erythematosus: a clinical marker for monitoring disease activity and damage. *Clin Exp Rheumatol* 20 (3):403-406
79. Abd-Elkareem MI, Al Tamimy HM, Khamis OA, Abdellatif SS, Hussein MR (2010) Increased urinary levels of the leukocyte adhesion molecules ICAM-1 and VCAM-1 in human lupus nephritis with advanced renal histological changes: preliminary findings. *Clin Exp Nephrol* 14 (6):548-557. doi:10.1007/s10157-010-0322-z

80. Howe HS, Kong KO, Thong BY, Law WG, Chia FL, Lian TY, Lau TC, Chng HH, Leung BP (2012) Urine sVCAM-1 and sICAM-1 levels are elevated in lupus nephritis. *Int J Rheum Dis* 15 (1):13-16. doi:10.1111/j.1756-185X.2012.01720.x
81. Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, Hojaili B, Mackay M, Aranow C, Stohl W, Rovin BH, Michaelson JS, Putterman C (2009) Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. *Arthritis Res Ther* 11 (5):R143. doi:10.1186/ar2816
82. Lu J, Kwan BC, Lai FM, Choi PC, Tam LS, Li EK, Chow KM, Wang G, Li PK, Szeto CC (2011) Gene expression of TWEAK/Fn14 and IP-10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. *Nephrology (Carlton)* 16 (4):426-432. doi:10.1111/j.1440-1797.2011.01449.x
83. Michaelson JS, Wisniacki N, Burkly LC, Putterman C (2012) Role of TWEAK in lupus nephritis: a bench-to-bedside review. *J Autoimmun* 39 (3):130-142. doi:10.1016/j.jaut.2012.05.003
84. Cheng E, Armstrong CL, Galisteo R, Winkles JA (2013) TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic. *Front Immunol* 4:473. doi:10.3389/fimmu.2013.00473
85. Xia Y, Herlitz LC, Gindea S, Wen J, Pawar RD, Misharin A, Perlman H, Wu L, Wu P, Michaelson JS, Burkly LC, Putterman C (2015) Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. *J Am Soc Nephrol* 26 (5):1053-1070. doi:10.1681/ASN.2014030233
86. Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, Michaelson JS, Rovin B, Putterman C (2006) Urinary TWEAK and the activity of lupus nephritis. *J Autoimmun* 27 (4):242-250. doi:10.1016/j.jaut.2006.12.003
87. Xuejing Z, Jiazhen T, Jun L, Xiangqing X, Shuguang Y, Fuyou L (2012) Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. *J Biomed Biotechnol* 2012:359647. doi:10.1155/2012/359647
88. Iwano M, Dohi K, Hirata E, Kurumatani N, Horii Y, Shiiki H, Fukatsu A, Matsuda T, Hirano T, Kishimoto T, et al. (1993) Urinary levels of IL-6 in patients with active lupus nephritis. *Clin Nephrol* 40 (1):16-21
89. Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY (2000) Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. *Nephron* 85 (3):207-214. doi:45663
90. Li Y, Tucci M, Narain S, Barnes EV, Sobel ES, Segal MS, Richards HB (2006) Urinary biomarkers in lupus nephritis. *Autoimmun Rev* 5 (6):383-388. doi:10.1016/j.autrev.2005.10.006
91. Enghard P, Humrich JY, Rudolph B, Rosenberger S, Biesen R, Kuhn A, Manz R, Hiepe F, Radbruch A, Burmester GR, Riemekasten G (2009) CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. *Arthritis Rheum* 60 (1):199-206. doi:10.1002/art.24136
92. Romagnani P, Beltrame C, Annunziato F, Lasagni L, Luconi M, Galli G, Cosmi L, Maggi E, Salvadori M, Pupilli C, Serio M (1999) Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. *J Am Soc Nephrol* 10 (12):2518-2526
93. Lu J, Szeto CC, Tam LS, Lai FM, Li EK, Chow KM, Li PK, Kwan BC (2012) Relationship of intrarenal gene expression and the histological class of lupus nephritis -- a study on repeat renal biopsy. *J Rheumatol* 39 (10):1942-1947. doi:10.3899/jrheum.120177

94. Avihingsanon Y, Phumesin P, Benjachat T, Akkasilpa S, Kittikowit V, Praditpornsilpa K, Wongpiyabavorn J, Eiam-Ong S, Hemachudha T, Tungsanga K, Hirankarn N (2006) Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. *Kidney Int* 69 (4):747-753. doi:10.1038/sj.ki.5000132
95. Brunner HI, Bennett M, Abulaban K, Klein-Gitelman M, O'Neil K, Tucker L, Ardoin S, Rouster-Stevens K, Onel K, Singer N, Eberhard BA, Jung L, Imundo L, Wright T, Witte D, Rovin B, Ying J, Devarajan P (2015) Development of a novel renal activity index of lupus nephritis in children & young adults. *Arthritis Care Res (Hoboken)*. doi:10.1002/acr.22762
96. Santucci L, Candiano G, Bruschi M, Bodria M, Murtas C, Petretto A, Ghiggeri GM (2013) Urinary proteome in a snapshot: normal urine and glomerulonephritis. *J Nephrol* 26 (4):610-616. doi:10.5301/jn.5000233
97. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P (2004) Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. *Kidney Int* 65 (1):323-332. doi:10.1111/j.1523-1755.2004.00352.x
98. Wu T, Mohan C (2009) Proteomic toolbox for autoimmunity research. *Autoimmun Rev* 8 (7):595-598. doi:10.1016/j.autrev.2009.01.019
99. Li Y, Fang X, Li QZ (2013) Biomarker profiling for lupus nephritis. *Genomics Proteomics Bioinformatics* 11 (3):158-165. doi:10.1016/j.gpb.2013.05.003
100. Mosley K, Tam FW, Edwards RJ, Crozier J, Pusey CD, Lightstone L (2006) Urinary proteomic profiles distinguish between active and inactive lupus nephritis. *Rheumatology (Oxford)* 45 (12):1497-1504. doi:10.1093/rheumatology/kei351
101. Oates JC, Varghese S, Bland AM, Taylor TP, Self SE, Stanislaus R, Almeida JS, Arthur JM (2005) Prediction of urinary protein markers in lupus nephritis. *Kidney Int* 68 (6):2588-2592. doi:10.1111/j.1523-1755.2005.00730.x
102. Zhang X, Jin M, Wu H, Nadasdy T, Nadasdy G, Harris N, Green-Church K, Nagaraja H, Birmingham DJ, Yu CY, Hebert LA, Rovin BH (2008) Biomarkers of lupus nephritis determined by serial urine proteomics. *Kidney Int* 74 (6):799-807. doi:10.1038/ki.2008.316
103. Suzuki M, Ross GF, Wiers K, Nelson S, Bennett M, Passo MH, Devarajan P, Brunner HI (2007) Identification of a urinary proteomic signature for lupus nephritis in children. *Pediatr Nephrol* 22 (12):2047-2057. doi:10.1007/s00467-007-0608-x
104. Sesso R, Rettori R, Nishida S, Sato E, Ajzen H, Pereira AB (1994) Assessment of lupus nephritis activity using urinary retinol-binding protein. *Nephrol Dial Transplant* 9 (4):367-371
105. Marks SD, Shah V, Pilkington C, Woo P, Dillon MJ (2005) Renal tubular dysfunction in children with systemic lupus erythematosus. *Pediatr Nephrol* 20 (2):141-148. doi:10.1007/s00467-004-1707-6
106. Gupta R, Yadav A, Misra R, Aggarwal A (2015) Urinary prostaglandin D synthase as biomarker in lupus nephritis: a longitudinal study. *Clin Exp Rheumatol* 33 (5):694-698
107. Mohammed MF, Belal D, Bakry S, Marie MA, Rashed L, Eldin RE, El-Hamid SA (2014) A study of hepcidin and monocyte chemoattractant protein-1 in Egyptian females with systemic lupus erythematosus. *J Clin Lab Anal* 28 (4):306-309. doi:10.1002/jcla.21685
108. Choe JY, Park SH, Kim SK (2014) Urine beta2-microglobulin is associated with clinical disease activity and renal involvement in female patients with systemic lupus erythematosus. *Lupus* 23 (14):1486-1493. doi:10.1177/0961203314547797
109. Wu T, Du Y, Han J, Singh S, Xie C, Guo Y, Zhou XJ, Ahn C, Saxena R, Mohan C (2013) Urinary angiotensin--a novel putative marker of renal pathology chronicity in lupus nephritis. *Mol Cell Proteomics* 12 (5):1170-1179. doi:10.1074/mcp.M112.021667

110. Fournier T, Bouach N, Delafosse C, Crestani B, Aubier M (1999) Inducible expression and regulation of the alpha 1-acid glycoprotein gene by alveolar macrophages: prostaglandin E2 and cyclic AMP act as new positive stimuli. *J Immunol* 163 (5):2883-2890
111. Sorensson J, Matejka GL, Ohlson M, Haraldsson B (1999) Human endothelial cells produce orosomucoid, an important component of the capillary barrier. *Am J Physiol* 276 (2):530-534
112. Shibata Y, Tamura K, Ishida N (1984) Cultured human monocytes, granulocytes and a monoblastoid cell line (THP-1) synthesize and secrete immunosuppressive acidic protein (a type of alpha 1-acid glycoprotein). *Microbiol Immunol* 28 (1):99-111
113. Nakamura T, Board PG, Matsushita K, Tanaka H, Matsuyama T, Matsuda T (1993) Alpha 1-acid glycoprotein expression in human leukocytes: possible correlation between alpha 1-acid glycoprotein and inflammatory cytokines in rheumatoid arthritis. *Inflammation* 17 (1):33-45
114. Gahmberg CG, Andersson LC (1978) Leukocyte surface origin of human alpha1-acid glycoprotein (orosomucoid). *J Exp Med* 148 (2):507-521
115. Cecilian F, Pocacqua V (2007) The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. *Curr Protein Pept Sci* 8 (1):91-108
116. Urade Y, Hayaishi O (2000) Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. *Biochim Biophys Acta* 1482 (1-2):259-271
117. Hellman NE, Gitlin JD (2002) Ceruloplasmin metabolism and function. *Annu Rev Nutr* 22:439-458. doi:10.1146/annurev.nutr.22.012502.114457
118. Baker JF, Ghio AJ (2009) Iron homeostasis in rheumatic disease. *Rheumatology (Oxford)* 48 (11):1339-1344. doi:10.1093/rheumatology/kep221
119. Navarro C, Candia-Zuniga L, Silveira LH, Ruiz V, Gaxiola M, Avila MC, Amigo MC (2002) Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. *Lupus* 11 (1):21-24
120. Ohara N, Hanyu O, Hirayama S, Nakagawa O, Aizawa Y, Ito S, Sone H (2014) Hypertension increases urinary excretion of immunoglobulin G, ceruloplasmin and transferrin in normoalbuminuric patients with type 2 diabetes mellitus. *J Hypertens* 32 (2):432-438. doi:10.1097/HJH.000000000000019
121. Norden AG, Lapsley M, Unwin RJ (2014) Urine retinol-binding protein 4: a functional biomarker of the proximal renal tubule. *Adv Clin Chem* 63:85-122
122. Delanghe JR, Langlois MR (2001) Hemopexin: a review of biological aspects and the role in laboratory medicine. *Clin Chim Acta* 312 (1-2):13-23
123. Fitzpatrick M, Young SP (2013) Metabolomics--a novel window into inflammatory disease. *Swiss Med Wkly* 143:w13743. doi:10.4414/smw.2013.13743
124. Romick-Rosendale LE, Brunner HI, Bennett MR, Mina R, Nelson S, Petri M, Kiani A, Devarajan P, Kennedy MA (2011) Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. *Arthritis Res Ther* 13 (6):R199. doi:10.1186/ar3530
125. Warrack BM, Hnatyshyn S, Ott KH, Reily MD, Sanders M, Zhang H, Drexler DM (2009) Normalization strategies for metabolomic analysis of urine samples. *J Chromatogr B Analyt Technol Biomed Life Sci* 877 (5-6):547-552. doi:10.1016/j.jchromb.2009.01.007